Partner Research Centers:


Center for Neurodegenerative Disease Research

Leslie M. Shaw

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Co-Director, Alzheimer's Disease Neuroimaging, Initiative Biomarker Core Laboratory, University of Pennsylvania
Interim Director, Clinical Chemistry Laboratory, Dept of Pathology & Laboratory Medicine, University of Pennsylvania
Co-Director Parkinson's Progression Markers Initiative Bioanalytics Core, University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Hospital of the University of Pennsylvania
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Education:
B.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Post-Graduate Training
NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970.
Fellow, Neuroscience Research Program, 1969-1969.
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972.
Certifications
American Board of Clinical Chemistry, 1973.
American Board of Clinical Chemistry in Toxicological Chemistry, 1990.
USC School of Medicine, Laboratory of Applied Pharmacokinetics , 1995.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42) and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.

Description of Clinical Expertise

Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.

Description of Other Expertise

Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including 25-OH vitamin D.

Selected Publications

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Dain-Hilaire M-H, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K, Kang UJ. : CSF, Plasma, and saliva in the BioFIND Study: relationships among biomarkers and Parkinson's disease features. Movement Disorders, in Press. 2017, In Press.

Irwin DJ, Sharon X Xie, Coughlin D, Nevier N, Akhtar R, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M,and Trojanowski JQ. : CSF Tau and Amyloid-Beta Predict Cerebral Synucleinopathy in Autopsied Lewy Body Disorders. Neurology, in Press. 2017, In Press Notes: Running Title: CSF Biomarkers in Autopsy-confirmed LBD.

Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ for the Alzheimer Disease Neuroimaging Initiative. : Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease. 58: 1245-1254, 2017 Notes: Accepted April 13, 2017.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu I-W, Zhang Y, Nalls M, Singleton A, Shaw LM, Kang J-H, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, and The Parkinson's Progressive Markers Initiative (PPMI). : Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson Disease. PLOS One 12(5), 2017 Notes: https://doi.org/10.1371/journal.pone.0175674.

Galasko DR and Shaw LM.: CSF Biomarkers for Alzheimer Disease - approaching consensus. Nature Reviews / NEUROLOGY 2017 Notes: http://dx.doi.org/10.1016/j.jalz.2016.09.009 (2016) E-Published ahead of print.

Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O'Hara R, Ashford JW, Shaw LM, Alzheimer's Disease Neuroimaging Initiative. : Active Cigarette smoking in cognitively-normal elders and probable Alzheimer's Disease is associated with Elevated Cerebrospinal fluid Oxidative Stress biomarkers. J Alzheimers Dis. Jul 25 2016 Notes: EPub ahead of print.

Bjerke M, Andreasson U, Kuhlman J, Portelius E, Pannee J, Lewczuk P, Umek RM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, Kostanjevecki V, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, Blennow K.: Assessing the commutability of reference material formats for the harmonization of amyloid-B measurements. Clin Chem Lab Med. 54(7), Jul 2016.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligorska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson's Progression Marker Initiative.: CSF Biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol. 131(6): 935-49, June 2016 Notes: EPub ahead of print - 2016/Mar 28.

Vilas D, Shaw LM, Taylor P, Berg D, Brockman K, Aasly J, Marras C, Pont-Sunyer C, Rios J, Marek K, Tolosa E.: Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Mov Disord. 31(6): 906-14, June 2016 Notes: EPub ahead of print - 2016/Apr 4.

Podlesniy P, Vilas D, Taylor P, Shaw LM, Tolosa E, Trullas R. : Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. Neurobiol Dis. 94: 10-17, May 31 2016 Notes: EPub ahead of print.

back to top
Last updated: 11/30/2017
The Trustees of the University of Pennsylvania